Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease.

Previous meta-analyses suggest that treatment with erythropoiesis-stimulating agents (ESAs) in chronic kidney disease (CKD) increases the risk for death. Additional randomized trials have been recently completed.